Please assess the completion status of the following clinical trial:

Trial Title: Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Add-On

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~1. Male or female patients \>= 45 years and able to provide informed consent (females must be either post-menopausal for one year, surgically sterile, or using effective contraception. Oral contraceptives are disallowed.)~2. Patients with type II diabetes with HbA1c ≤ 9.0 on stable anti-glycemic regimen that may include oral and/or injectable therapy (GLP-1/Insulin etc.). Changes in dose of glycemic regimen is allowed during the course of the trial if felt to be clinically appropriate.~3. Glomerular filtration rate (GFR) \<90 and evidence of proteinuria (Urine Albumin/Creatinine Ratio of \>30 mg/g or equivalent) in a urine specimen within 12 months OR GFR \<60 mg/g regardless of proteinuria~4. Patients must be on angiotensin-converting-enzyme inhibitor (ACE) and/or angiotensin-resistance-blocker (ARB) therapy with no planned dose adjustments.~5. Hyperkalemia defined as serum K+≥ 5.1 meq/L at visit 0 (screening).~Exclusion Criteria~1. Uncontrolled hypertension (Systolic Blood Pressure (SBP)\>160 and/or Diastolic Blood Pressure (DBP)\>95 mmHg at visit 0 (screening) and SBP \>145 mm Hg at visit 2).~2. GFR (MDRD) of \<20 at visit 0 (screening)~3. Hyperkalemia defined as serum K+ \<5.1 meq/L at visit 0 (screening).~4. LDL cholesterol \>150 mg/dL~5. Plasma triglycerides \> 400 mg/dl~6. Contraindications to MRI (metallic implants, severe claustrophobia).~7. Acute coronary syndrome, Transient ischemic attack, cardiovascular accident (CVA) or critical limb ischemia during the last 6 months or coronary/peripheral revascularization within the last 3 months.~8. Evidence of a secondary form of hypertension.~9. Initiation of new therapy with statins, ACE/ARB, antioxidants, calcium channel blockers (CCBs), diuretics, β blockers.~10. Type I diabetes mellitus~11. Known contraindication, including history of allergy to Spironolactone or Patiromer~12. Any surgical or medical condition which might alter pharmacokinetics of drug (e.g. renal transplant, liver failure, liver transplant)~13. Concurrent potentially life threatening arrhythmia or symptomatic arrhythmia.~14. Significant hyponatremia defined as Na \<130 meq/L.~15. History of prior malignancy including leukemia and lymphoma (but not basal cell skin cancer, cured squamous cell cancer and cured prostate cancer).~16. History of any severe, life-threatening disease.~17. Any surgical or medical conditions which place the patient at higher risk derived from his/her participation into the study, or likely to prevent patient from complying with requirements.~18. History of drug abuse within the last 2 years, noncompliance and unwillingness/inability to consent.~19. Pregnant women and nursing mothers~20. Class III or IV Congestive Heart Failure~21. Primary Hyperaldosteronism

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patiromer Add-On (Type: EXPERIMENTAL): Single arm experimental study in 50 diabetic patients with chronic kidney disease and hyperkalemia.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues